Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects

Netherlands Heart Journal

Volumn 17, Issue 5, 2009, Pages 195-198

  Bouman, H J ^a   Van Werkum, J W ^a   Hackeng, C M ^a   Clappers, N ^b   Ten Berg, J M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cangrelor; Clopidogrel; P2Y12; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CANGRELOR; CLOPIDOGREL;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG POTENTIATION; FEMALE; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

EID: 70349286301     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03086246     Document Type: Article

References (12)

1. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896 (Pubitemid 30946954)
2. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-238
3. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251 (Pubitemid 40094733)
4. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27:2420-2425 (Pubitemid 44522148)
5. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48:1339-1345 (Pubitemid 44436814)
6. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317 (Pubitemid 46891710)
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015 (Pubitemid 350106708)
8. Fugate SE, Cudd LA. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 2006;40:925-930
9. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001;12:443-447 (Pubitemid 33097240)
10. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001;85:401-407
11. van Werkum JW, Hackeng CM, de Korte FI, Verheugt FW, Ten Berg JM. Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place. Neth Heart J 2007;15:299-305.
12. van Werkum JW, Kleibeuker M, Mieremet N, Ten Berg JM, Hackeng CM. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? J Thromb Haemost 2007;5:884-886 (Pubitemid 46563599)